1jp2: Difference between revisions
No edit summary |
No edit summary |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Theoretical_model}} | {{Theoretical_model}} | ||
==MOLECULAR DOCKING OF COMPETITIVE PHOSPHODIESTERASE INHIBITOR, 4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-2- PYRROLIDINONE, ROLIPRAM== | |||
<StructureSection load='1jp2' size='340' side='right'caption='[[1jp2]]' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1JP2 FirstGlance]. <br> | |||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1jp2 FirstGlance], [https://www.ebi.ac.uk/pdbsum/1jp2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1jp2 ProSAT]</span></td></tr> | |||
-- | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Mammalian phosphodiesterases types 3 and 4 (PDE3 and PDE4) hydrolyze cAMP and are essential for the regulation of this intracellular second messenger. These enzymes share structural and biochemical similarities, but each can be distinguished by its sensitivity to isoenzyme-specific, substrate-competitive inhibitors. We present a model configuration for the PDE4 substrate (cAMP) and a PDE4-specific inhibitor (rolipram) within the active site of the enzyme. The docked models were also used to examine the structural consequences of mutations that confer resistance to rolipram and other PDE4-specific inhibitors. The proposed rolipram-binding configuration is consistent with the substrate-competitive nature of inhibition and also provides a structural basis for the observed specificity of binding to the R- versus S-enantiomer. For mutations that render the enzyme rolipram-insensitive, there was generally an inverse relationship between the magnitude of the drug resistance and the distance of the altered residue from the predicted binding site. We observed a direct correlation between the net loss of protein residue interactions (van der Waals contacts and hydrogen bond interactions) and the degree of rolipram resistance. The positions of several drug sensitivity-determinant residues define a surface leading to the substrate- and drug-binding sites, suggesting a possible approach channel leading to the enzyme active site. The binding of other PDE4 inhibitors (high- and low-affinity) was also modeled and used to predict the involvement of residues that were not previously implicated in pharmacological interactions. | |||
Molecular docking of competitive phosphodiesterase inhibitors.,Dym O, Xenarios I, Ke H, Colicelli J Mol Pharmacol. 2002 Jan;61(1):20-5. PMID:11752202<ref>PMID:11752202</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 1jp2" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
== | [[Category: Theoretical Model]] | ||
[[Category: Large Structures]] | |||
== | |||
< | |||
[[Category: Colicelli, J]] | [[Category: Colicelli, J]] | ||
[[Category: Dym, O]] | [[Category: Dym, O]] | ||
[[Category: Ke, H]] | [[Category: Ke, H]] | ||
[[Category: Xenarios, I]] | [[Category: Xenarios, I]] | ||
Latest revision as of 09:43, 11 August 2021
 |
MOLECULAR DOCKING OF COMPETITIVE PHOSPHODIESTERASE INHIBITOR, 4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-2- PYRROLIDINONE, ROLIPRAMMOLECULAR DOCKING OF COMPETITIVE PHOSPHODIESTERASE INHIBITOR, 4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]-2- PYRROLIDINONE, ROLIPRAM
Structural highlights
Publication Abstract from PubMedMammalian phosphodiesterases types 3 and 4 (PDE3 and PDE4) hydrolyze cAMP and are essential for the regulation of this intracellular second messenger. These enzymes share structural and biochemical similarities, but each can be distinguished by its sensitivity to isoenzyme-specific, substrate-competitive inhibitors. We present a model configuration for the PDE4 substrate (cAMP) and a PDE4-specific inhibitor (rolipram) within the active site of the enzyme. The docked models were also used to examine the structural consequences of mutations that confer resistance to rolipram and other PDE4-specific inhibitors. The proposed rolipram-binding configuration is consistent with the substrate-competitive nature of inhibition and also provides a structural basis for the observed specificity of binding to the R- versus S-enantiomer. For mutations that render the enzyme rolipram-insensitive, there was generally an inverse relationship between the magnitude of the drug resistance and the distance of the altered residue from the predicted binding site. We observed a direct correlation between the net loss of protein residue interactions (van der Waals contacts and hydrogen bond interactions) and the degree of rolipram resistance. The positions of several drug sensitivity-determinant residues define a surface leading to the substrate- and drug-binding sites, suggesting a possible approach channel leading to the enzyme active site. The binding of other PDE4 inhibitors (high- and low-affinity) was also modeled and used to predict the involvement of residues that were not previously implicated in pharmacological interactions. Molecular docking of competitive phosphodiesterase inhibitors.,Dym O, Xenarios I, Ke H, Colicelli J Mol Pharmacol. 2002 Jan;61(1):20-5. PMID:11752202[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References |
| ||||||||||||||